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A chimeric simian-human immunodeficiency virus (SHIV-4) containing the tat, rev, vpu, and env genes of HIV type 1 (HIV-1)
in a genetic background of SIVmac239 was used to develop an animal model in which a primate lentivirus expressing the HIV-1
envelope glycoprotein caused acquired immune deficiency syndrome (AIDS) in macaques. An SHIV-infected pig-tailed
macaque that died from AIDS at 24 weeks postinoculation experienced two waves of viremia: one extending from weeks 2–8
and the second extending from week 18 until death. Virus (SHIVKU-1) isolated during the first wave was neutralized by
antibodies appearing at the end of the first viremic phase, but the virus (SHIVKU-1b) isolated during the second viremic phase
was not neutralized by these antibodies. Inoculation of SHIVKU-1b into 4 pig-tailed macaques resulted in severe CD4
1 T cell
loss by 2 weeks postinoculation, and all 4 macaques died from AIDS at 23–34 weeks postinoculation. Because this virus had
a neutralization-resistant phenotype, we sequenced the env gene and compared these sequences with those of the env gene
of SHIVKU-1 and parental SHIV-4. With reference to SHIV-4, SHIVKU-1b had 18 and 6 consensus amino acid substitutions in the
gp120 and gp41 regions of Env, respectively. These compared with 10 and 3 amino acid substitutions in the gp120 and gp41
regions of SHIVKU-1. Our data suggested that SHIVKU-1 and SHIVKU-1b probably evolved from a common ancestor but that
SHIVKU-1b did not evolve from SHIVKU-1. A chimeric virus, SHIVKU-1bMC17, constructed with the consensus env from the
SHIVKU-1b on a background of SHIV-4, confirmed that amino acid substitutions in Env were responsible for the neutralization-
resistant phenotype. These results are consistent with the hypothesis that neutralizing antibodies induced by SHIVKU-1 in
pig-tailed macaque resulted in the selection of a neutralization-resistant virus that was responsible for the second wave of
viremia. © 1999 Academic Press
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The development of neutralization-escape virus vari-
nts is a relatively common phenomenon in lentivirus
nfections. First recognized during infection with proto-
ypic lentiviruses such as equine infectious anemia virus
nfection in horses (Kono et al., 1988) and maedi visna
irus infection in sheep (Gudnadottir, 1974; Narayan et
l., 1977), the phenomenon has been identified subse-
uently in humans infected with human immunodefi-
iency virus type 1 (HIV-1) (Robert-Guroff et al., 1986) and
n macaques infected with simian immunodeficiency vi-
us (SIV) (Burns et al., 1993; Joag et al., 1993; Zhang et al.,
993). Mechanistically, the variants are thought to evolve
y a two-stage process involving, first, mutations in the
irus genome and, second, selection of mutants by an-
ibodies (Leroux et al., 1997; Payne et al., 1987). Although
utations are common during the replication of all RNA
iruses (Holland and Domingo, 1998), such genomic
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ntario, Canada.
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54hanges have profound effects in the pathogenesis of
entiviral infections because the natural history of the
vent occurs in the infected individual rather than in the
opulation, as seen in epidemics of influenza A virus
nfections. Proofreading mistakes during reverse tran-
cription of lentiviral RNA to proviral DNA followed by
ntegration of the viral DNA into host DNA provides a
emplate for indefinite production of aberrant viruses in
n individual host. Random mutations lead to emergence
f well known heterogeneous lentiviral swarms consist-
ng of biologically distinct phenotypes, including viruses
ith different cell and tissue tropisms. Neutralizing anti-
odies appearing during the infection then select a new
eterogeneous swarm dominated by the antibody-es-
ape phenotypes caused by viruses with mutations with
he env gene. This event has the potential for extending
he productive phase of virus replication with accelera-
ion in the onset of disease.
Prospects for development of a vaccine against HIV-1
re complicated by the phenomenon of evolution of an-
ibody-escape variant viruses because of the diversity of
ntigenic types of viruses that are generated by the
rocess and the uncertainty of whether a vaccine thatnduces protection against one type will protect against
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55ANTIGENIC VARIATION IN SHIVeterogeneous types. However, despite extensive ge-
eric studies on the biology of lentiviral envelope glyco-
roteins, which contain the epitopes that elicit neutraliz-
ng antibodies, only limited biological evaluation could
e performed on the env of HIV-1 with respect to patho-
enic outcome of infection or immunity to the virus be-
ause of the inability of HIV-1 to replicate productively in
osts other than humans. The construction of SHIV con-
aining the env gene of HIV-1 in a background of SIV has
rovided a mechanism for studying the biology of the HIV
nv gene during experimental infection in macaques.
he derivation of pathogenic SHIVs further enhanced the
alue of the SHIV model because the methods were
vailable to evaluate mutations in the env gene of HIV-1
ithin the context of viral transmission, pathogenesis,
nduction of immune responses, and the effector role of
eutralizing antibodies in the selection of antibody-es-
ape viruses (Etemad-Moghadam et al., 1998; Foresman
t al., 1998; Joag et al., 1997a, 1997b, 1998; Montefiori et
l., 1998).
In this report, we describe the isolation of an antibody-
scape pathogenic SHIV in a fatally infected macaque
nd report on the construction of a new SHIV chimera
ith the env gene of this antibody escape variant to
onfirm its neutralization-resistant phenotype. This new
odel provides a system in which the biological effects
f antigenically important neutralization epitopes of
IV-1 envelope can be evaluated in causation or preven-
ion of infection or disease using the macaque evaluation
ystem.
RESULTS
solation of SHIVKU-1b and its neutralization-resistant
henotype
Both SHIVKU-1 and SHIVKU-1b were isolated for pig-
ailed macaque (PNb) that had been inoculated with
one marrow cells from macaques PPc and PQc. Ma-
aque PNb developed a high virus burden accompanied
y loss of CD41 T cells during the first 2 weeks (Fig. 1).
he frequency of infectious cells in blood reached 104/
06 at week 2, and the infectious virus titer in plasma was
0 TCID50/ml. By week 9, the CD4
1 T cell count had
allen to ,150/ml, and SHIVKU-1 was isolated from cere-
rospinal fluid obtained at this time. Infectious virus in
lasma disappeared after week 8 but reappeared at
eek 18. The second rise in infectious viremia coincided
ith a further fall in the CD41 T cell count and the onset
f clinical disease. Plasma obtained before week 8 had
eutralizing antibodies to SHIV-4 and HIV-1 HxB3 but not
o SHIVKU-1 (Fig. 2). The antibody titers against SHIV-4
nd HIV-1 HxB3 peaked at week 18 and then fell. In
ontrast, neutralizing antibody titers to SHIVKU-1 first be-
ame detectable at week 9, and the titer reached its
ighest level at week 20 until death of the animal. Theow virus burdens in plasma between weeks 8–18 coin- wided with increasing titer of neutralizing antibodies to
HIVKU-1. Virus resurgence after week 18 occurred in the
resence of the neutralizing antibodies to SHIVKU-1. The
nimal developed AIDS and was euthanized at week 24.
Plasma obtained at week 24 from macaque PNb con-
ained both virus (SHIVKU-1b) and antibodies to SHIVKU-1.
irus was isolated from this plasma and biologically
loned twice by limiting dilution in CEMx174 cells. This
loned virus was then amplified in peripheral blood
ononuclear cells (PBMCs) from a normal macaque and
esignated SHIVKU-1b. Antibodies in the week-24 plasma
eutralized SHIVKU-1 at a titer of 1:320 but failed to neu-
ralize SHIVKU-1b at a dilution of 1:5 or higher (Table 1). In
ontrast, plasma isolated from early passages of SHIV-4
n macaques (8A, PLc, PRc, PPc, PQc) all had antibodies
hat neutralized SHIV-4, SHIVKU-1, and SHIVKU-1b
Table 1).
In previously reported studies (Joag et al., 1996, 1997b),
ig-tailed macaques inoculated with SHIVKU-1 all devel-
ped CD41 T cell loss within 4 weeks and AIDS, in most
ases, within 8 months postinoculation. In 3 (18B, 18D,
nd 18E) SHIVKU-1-inoculated animals, a late phase of
lasma viremia similar to that seen in macaque PNb was
etected (Table 2). None of the 3 animals developed
eutralizing antibodies to either SHIVKU-1 or SHIV-4. Virus
as isolated from the final plasma of the 3 animals and
irus stocks prepared in CEMx174 cells. All three viruses
ere neutralized by week 24 plasma from macaque PNb
t the same dilution as SHIVKU-1 (1:320), suggesting that
hese viruses were antigenically similar to SHIVKU-1.
HIVKU-1b is pathogenic for pig-tailed macaques
Four pig-tailed macaques, 40J, 40K, 40L, and 40M,
ere inoculated intravenously with 10,000 TCID50
HIVKU-1b, and blood was obtained at regular intervals to
onitor virus burden and CD41 T cell counts. At 2 weeks
ostinoculation, all 4 animals developed severe CD41 T
ell loss accompanied by high virus burdens (Table 3).
acaque 40J developed AIDS at week 23, whereas the
emaining animals developed AIDS between weeks 33
nd 34. None of the 4 animals developed neutralizing or
mmunoprecipitating antibodies to SHIVKU-1b, SHIVKU-1,
r SHIV-4 (data not shown).
equence analysis of the SHIVKU-1b env gene
Because of the neutralization-resistant phenotype of
HIVKU-1b, we compared the consensus amino acid sub-
titutions in the env genes of this virus with those of the
eutralization-sensitive SHIVKU-1 and with the env gene
f parental SHIV-4. The SHIVKU-1b and SHIVKU-1 gp120
egions of Env had 18 and 10 consensus amino acid
ubstitutions, respectively, compared with SHIV-4 (Fig. 3).
he SHIVKU-1b and SHIVKU-1 gp41 regions of Env had 6
nd 3 amino acid substitutions, respectively, compared
ith SHIV-4. Of the 10 consensus amino acid substitu-
o
a
56 NARAYAN ET AL.FIG. 1. Comparison of the gp160 sequence from SHIV-4 (strain HXB2) with the predicted amino acid sequences derived from sequence analysis
f SHIVKU-1b gp160 clones. Shown above the sequences of the five SHIVKU-1b env clones is the sequence of HXB2 gp160 sequence. Dashes represent
mino acid identity. For comparative purposes, brackets corresponding to variable regions V1–V5 were placed above the gp160 sequence.
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57ANTIGENIC VARIATION IN SHIVions in the gp120 of SHIVKU-1, 7 were also found in
HIVKU-1b, whereas all 3 consensus amino acid changes
n the gp41 of SHIVKU-1 were found in SHIVKU-1b.
eutralization of SHIVKU1bMC17
SHIVKU1bMC17 was constructed as described by ex-
hanging the env gene of SHIVKU-1b (clone 2) with that of
FIG. 2. CD41 T cell count (left axis), infectious PBMC frequency, and
Nb.
TABLE 1
eutralizing Antibody Titers against SHIV-4, SHIVKU-1, and SHIVKU-1b
in Plasma from Early Passage Macaques and Macaque PNb
Macaque Passagea vs SHIV-4 vs SHIVKU-1 vs SHIVKU-1b
8A 1 270 270 160
PLc 2 270 70 20
PRc 2 540 140 80
PPc 3 380 60 70
PQc 3 160 110 100
PNb 4 80 320 ,10
Note. Plasma for neutralization assays was obtained from macaques
A, PLc, and PRc between 18 and 24 months postinoculation. These
nimals remained healthy. The other 3 animals developed AIDS, and
lasma was obtained at necropsy.fa Refers to animal passage of SHIV-4 virus.HIV-4. The DNA of the new chimera was transfected
nto C8166 cells, and the resulting cytopathic virus ex-
anded by a further passage in these cells. Neutraliza-
ion tests using this virus showed that it failed to be
eutralized by antibodies in serum for macaque PNb at 8
nd 24 weeks (#1:10) but was neutralized by serum from
acaque 8A, the animal inoculated with the molecular
lone SHIV-4 infected with SHIV-4. The neutralization
attern of the chimera was very similar to that of
HIVKU-1b.
DISCUSSION
In this report, using sequentially collected blood sam-
les from the macaque that had yielded SHIVKU-1 (Joag et
l., 1996), we identified and characterized a second new
athogenic virus, SHIVKU-1b, antigenically distinct from
he antecedent SHIVKU-1. We used the env gene of
HIVKU-1b to create a new chimera, SHIVKU-1bMC17, that
as the neutralization phenotype of SHIVKU-1b. This new
irus provides the potential for functional evaluation of
articular mutations in the env gene with reference to
nduction of, or response to, new neutralizing antibodies
eveloping in new animals infected with this virus. The
infectivity (both plotted against the right axis) in blood from macaqueplasmaact that SHIVKU-1b is also pathogenic allows for func-
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58 NARAYAN ET AL.ional evaluation of these changes within the context of
isease and prevention of disease.
Macaque PNb, from which SHIVKU-1 was isolated at
eek 9 postinoculation, developed high neutralizing an-
ibody titers to SHIVKU-1. During a later stage in infection,
etween weeks 18–24, this animal developed a second
ave of infectivity in plasma in the face of the neutraliz-
ng antibodies to SHIVKU-1. Virus isolated from the
lasma at this time was resistant to neutralization with
he antibodies that neutralized SHIVKU-1. The new neu-
ralization-escape virus was named SHIVKU-1b. This virus
as biologically cloned twice and then inoculated into 4
ew macaques, all of which became fatally infected,
TABLE 2
Plasma Infectivity and p27 Levels in Three Pig-Tailed Macaques
(18B, 18D, and 18E) Inoculated with SHIVKU-1
eek
p.i.a
Infectivity
(TCID50/ml)
p27
(pg/ml)
18B 18D 18E 18B 18D 18E
1 0 10 0 0 758 313
2 1000 0 0 7275 498 285
4 0 100 10 0 0 0
6 0 100 0 0 0 0
8 10 0 0 0 0 0
10 0 0 10 0 0 0
12 0 10 0 0 58 0
16 100 100 0 208 558 165
22 10 100 0 51 341 118
31 Died Died 100 Died Died 1493
a Refers to time postinoculation.
T
CD41 T Cell Counts and Frequency of
in Macaques (40L, 40K, 40L, a
Week
CD41 Cells/ml Blood
40J 40K 40L 4
0 546 1924 1464
1 308 689 240
2 16 ,10 36
4 50 ,10 ,10 ,
6 415 ,10 39 ,
8 151 ,10 39
10 300 ,10 74
12 42 240 330
14 38 ,10 80
18 26 112 63 ,
22 38 366 45
25 19 ,10 ,
29 12 70 ,
33–34 ,10 ,10 ,
a Numbers of cells producing infectious virus per 106 PBMCs.
b N.D., not done.imilar to other animals infected with SHIVKU-1 (Joag et
l., 1997, 1996). To confirm the neutralization phenotype
f SHIVKU-1b, we created a new chimera by replacing the
HIV-4 env gene with that of SHIVKU-1b. The unique neu-
ralization characteristics from the SHIVKU-1b were also
pparent in the new chimera, SHIVKU-1bMC17.
It appears that the original SHIV-4 construct was a
otent inducer of neutralizing antibodies that were in all
ikelihood subtype and strain specific. This was reflected
y the ability of serum from SHIV-4-inoculated macaque
A (passage 1 of this virus) and sera from others infected
ith passage 2 material (Table 1) to neutralize SHIVKU-1
nd SHIVKU-1b, even though these animals were not ex-
osed to SHIVKU-1 or SHIVKU-1b. Macaque PNb, which
as inoculated with material from passage 3 animals,
lso developed neutralizing antibodies to SHIV-4 early
fter inoculation, but these antibodies did not neutralize
HIVKU-1, which presumably became dominant a few
eeks later (Fig. 1). It is possible that these early neu-
ralizing antibodies selected SHIVKU-1. Subsequently,
eutralizing antibodies to SHIVKU-1 appeared, and in turn,
hese may have selected SHIVKU-1b as a neutralization-
esistant variant. SHIVKU-1 is an extremely virulent virus
hat causes severe immunosuppression and acquired
mmune deficiency syndrome (AIDS). None of 10 pig-
ailed macaques inoculated with this virus developed
eutralizing antibodies, so there was no selective pres-
ure applied to the viral swarm. It therefore is not sur-
rising that the late viruses isolated from other ma-
aques, such as 18B, 18D, and 18E, maintained the same
eutralization profile as SHIVKU-1. However, because
HIVKU-1b was neutralized by antibodies induced by the
in PBMCs Producing Infectious Virus
M) Inoculated with SHIVKU-1b
aInfectious PBMCs/106
40J 40K 40L 40M
N.D.b N.D. N.D. N.D.
1000 10 1000 1000
10 100 100 10
100 10 10 10
10 10 10 100
5 5 10 100
10,000 1000 10,000 1000
10 10 10 4
10 1 10 3
3 0 10 1000
100 100 100 100
10 5 10
10 100 10
10 10 100ABLE 3
Cells
nd 40
0M
826
67
69
10
10
24
160
613
17
10
37
10
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59ANTIGENIC VARIATION IN SHIVarental virus SHIV-4, it is apparent that SHIVKU-1b is an
ntigenic escape virus only in the context of the infection
n macaque PNb, which either failed to develop or lost
lasma cells responsible for producing antibodies to
nique epitopes of SHIVKU-1b. Our results using SHIV-4,
ontaining the env from the laboratory-adapted T cell
ropic HXB2 strain of HIV-1, differ somewhat from those
ith macaques inoculated with SHIV-89.6, whose env
as derived from dual-tropic primary isolate. It was
hown that multiple passages of SHIV-89.6 gave rise to
he pathogenic variant SHIV-89.6P that resisted neutral-
zation by sera from animals infected with parental SHIV-
9.6 (Montefiori et al., 1998). It was subsequently shown
hat the neutralization-resistant phenotype of the SHIV-
9.6P mapped to the epitopes in the V2 and V3 regions
f the gp120 (Etemad-Maghadan et al., 1998). Whether
he differences in the neutralization profiles of SHIVKU-1b
nd SHIV-89.6P are related to the origin of the env genes
sed to generate these parental SHIVs remains to be
etermined.
Sequence analysis of SHIVKU-1b envelope identified
he amino acid substitutions in the Env that were asso-
iated with the neutralization escape phenotype. Previ-
us studies have identified several epitopes on the
FIG. 3. Neutralizing antibody titers in plasma fromp120 and gp41 regions of Env that are important for antibody-mediated virus neutralization and have estab-
ished that single amino acid changes occurring within
eutralization epitopes can affect recognition by comple-
entary antibodies and confer resistance to neutraliza-
ion (Broliden et al., 1992; Javaherian et al., 1989; Sullivan
t al., 1993; Thali et al., 1991; Tilley et al., 1991; Watkins et
l., 1996; Wyatt and Sodroski, 1998). The most intensively
tudied domain of the HIV-1 glycoprotein has been the
3 domain of gp120. This domain has both conforma-
ional and linear antigenic determinants that are altered
uring development of the immune escape variants
Langedijk et al., 1995; Schreiber et al., 1997b). Studies
ave shown that the antibodies generated against the V3
omain are predominately to a discontinuous epitope
nd suggest that progression into AIDS is associated
ith a loss of antibody reactivity directed against this
omain (Schreiber et al., 1996, Schreiber et al., 1997a).
lthough both SHIVKU-2 and SHIVKU-1b had four amino
cid substitutions in the V3 domain, the amino acid
equences differed at residues 310 and 325 (Fig. 3). The
1, V2 domain also contains both linear and conforma-
ional epitopes for virus-neutralizing antibodies (Fung et
l., 1992; McKeating et al., 1993a; Sullivan et al., 1993),
nd this region contains conserved epitopes that medi-
e PNb against HIV-1 HxB3, SHIV-4, and SHIVKU-1.te neutralization of primary isolates (Pinter et al., 1998).
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60 NARAYAN ET AL.he V1, V2 region of SHIVKU-1bMC17 env had three addi-
ional amino acid substitutions that were not present in
HIVKU-1 (Fig. 3). The glycosylation of potential N-linked
ites has been shown to influence the correct folding of
he V1, V2, V3, and C-terminal regions of gp120 and in
ecognition by neutralizing antibodies (Back et al., 1994;
emming et al., 1996; Warrier et al., 1994; Wu et al., 1995).
hether the addition of a potential N-glycosylation site at
osition 130 within the V1, V2 domain and the loss of
otential N-glycosylation sites at positions 288 and 339
n the SHIVKU-1b Env could have added and removed
arbohydrate residues that may have affected envelope
onformation and altered affinity of neutralizing antibod-
es remains to be determined. The discontinuous CD4-
inding site of gp120 also is an important target of
eutralizing antibodies (Wyatt and Sodroski, 1998). How-
ver, none of the amino acid residues shown to be
ritical for CD4 binding were altered in the SHIVKU-1b Env
Olshevsky et al., 1990). In addition to gp120, neutralizing
onoclonal antibodies have identified epitopes on the
p41 subunit of Env (.; Buratti et al., 1998; Conley et al.,
994; Cotropia et al., 1996; zharv.Purtscher et al., 1994).
one of the previously identified epitopes had amino
cid substitutions in SHIVKU-1b, although one of the con-
erved antigenic sites in gp41 (amino acid sequence
EEE) was altered (to amino acid sequence TEEE) in
HIVKU-1b. Whether amino acid substitutions in one or
ore of the regions were responsible for the neutraliza-
ion-resistant phenotype of SHIVKU-1b is unknown.
Our results suggest that the block in replication of
HIVKU-1 by neutralizing antibodies may have resulted in
sequential series of mutations and selection by anti-
odies of different viruses during the 15-week period
eparating the isolation of the two viruses. Thus the
rigin of SHIVKU-1b may have been the end result of the
ccumulation of numerous mutations in the env of this
irus. Further passage of the new chimera containing the
nvelope of SHIVKU-1b in new macaques will provide new
nsights into the patterns of neutralization-escape mech-
nisms that may be predictive of HIV-1 itself because
HIV carries the envelope of HIV-1. This will be of value
n the design of multiepitopic vaccines against this virus.
ven though neutralizing antibodies to lentiviruses are
neffective in controlling established infections, given the
ecent success in preventing SHIVKU infection in ma-
aques by the pretreatment of animals with antibodies to
he virus (Foresman et al., 1998), the way seems clear for
accines that induce long-lasting neutralizing antibodies
o be efficacious in preventing HIV-1 infection.
MATERIALS AND METHODS
iruses
We obtained SHIV-4 DNA encoding the env, tat, rev,
nd vpu genes of HIV-1 HXBc2 on a background of
IVmac239 (Li et al., 1992) from Dr. Joseph Sodroski (Har- mard University, Boston, MA). Viral DNA was transfected
nto CEMx174 cells to produce a virus that was used to
nitiate passage in macaques. Virus (SHIVKU-1) isolated
rom cerebrospinal fluid of pig-tailed macaque PNb at
eek 9 after inoculation during in passage 4 was ampli-
ied in culture of PBMCs from a normal macaque (Joag et
l., 1996). Virus was also isolated from plasma of this
nimal at week 24 immediately before it was euthanized.
his virus was biologically cloned twice, using the limit-
ng dilution approach, and then amplified again in PBMC
ulture from a normal macaque. Supernatant fluid from
his culture (SHIVKU-1b) had a titer of 10
4 TCID50/ml in
BMCs and CEMx174 and C8166 cells. Aliquots of this
HIVKU-1b stock were stored in liquid nitrogen. Stocks for
HIV-4, SHIVKU-1, SHIVKU-1b, and HIV-1 HxB3 intended for
eutralization assays were prepared in CEMx174 cells.
ell cultures
Human T cell line C8166 was used as indicator cells to
easure virus infectivity. Cells were cultured at a con-
entration of 1 3 106/ml in RPMI medium (RPMI supple-
ented with 10 mM HEPES buffer, pH 7.3, 50 mg/ml
entamicin, 5 3 1025 M 2-mercaptoethanol, and 2 mM
lutamine) with 10% FBS.
irus-neutralization assays
Serial doubling dilutions, starting with 1:10 of heat-
nactivated serum or plasma, were prepared in RPMI
edium, and 100 ml of each dilution was added to 4
ells of a 96-well flat-bottom microtiter plate. Virus stock
as diluted to 200 TCID50/ml, and 50 ml of this prepara-
ion (10 TCID50) was added to each well. The plate was
ncubated at 37°C for 1 h, after which 50 ml of a suspen-
ion of indicator C8166 cells, at a concentration of 2 3
05 cells/ml, was added. Each time, the diluted virus
reparation was titrated in medium alone to ensure that
ufficient virus was present to produce cytopathic effects
CPE) in each well. The absence of CPE in any well was
herefore attributable to the presence of neutralizing an-
ibodies. Plates were observed for CPE 7 days later, and
ells were scored individually. The antibody dilution at
hich half the wells showed CPE, the 50% neutralization
nd point (50% NEP), was calculated using the Ka¨rber
ethod (Lennette, 1969). The neutralizing antibody titer
f the plasma was the reciprocal of the antibody dilution
t 50% NEP.
noculation of macaques with SHIVKU-1b
Pig-tailed macaques (40J, 40K, 40L, and 40M) (Macaca
emestrina) were obtained from the Oregon Primate Re-
earch Center and were inoculated intravenously with 1
l (10,000 TCID50) of SHIVKU-1b.
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61ANTIGENIC VARIATION IN SHIVrocessing of PBMCs and virus assays
Peripheral blood obtained from the femoral vein was
ollected in heparinized syringes and centrifuged to sep-
rate plasma and buffy coats. Peripheral blood mononu-
lear cells (PBMCs) were separated from buffy coats by
entrifugation through a Ficoll–Paque (Pharmacia) den-
ity gradient. Infectious cell frequency was measured by
noculation of serial 10-fold dilutions of PBMCs, starting
ith 1 3 106 cells into 24-well tissue culture plates
ontaining 1 3 105 indicator C8166 T cells. These were
bserved for the development of syncytial CPE during a
-day period, after which cells and supernatant fluid in
00 ml from each well were transferred to another plate,
resh indicator cells were added, and these were ob-
erved for an additional 7 days (Joag et al., 1996). Results
ere expressed as the number of infectious cells/106
BMCs.
Plasma was assayed for p27 using a capture ELISA kit
Coulter Laboratories, Hialeah, FL) and for infectivity by
noculation of serial 10-fold dilutions of plasma into
8166 indicator cell cultures that were examined for CPE
or 7 days, after which cells and supernatant fluid in 100
l from each well were transferred to another plate. Then
resh indicator cells were added, and these were ob-
erved for an additional 7 days (Joag et al., 1996).
PBMCs or lymph node cells were reacted with mono-
lonal antibody to CD4 or CD8. After washing, the cells
ere stained with FITC-conjugated goat anti-mouse IgG,
ixed in 1% buffered formalin, and analyzed on a fluores-
ence-activated cell counter (Joag et al., 1994).
CR amplification, cloning, and analysis of the
HIVKU-1b env
C8166 cells were inoculated with SHIVKU-1b at a mul-
iplicity of 0.1 and after 2 days incubated at 37°C. Infected
ells (5 3 106 cells) were pelleted, and high-molecular-
eight DNA was extracted using standard protocols.
The PCR was used to amplify the entire env and part
f the nef gene of the virus using oligonucleotide primers
9-GACTAATAGAAAGAGCAGAAGACAGTGGCA-39 (sense)
nd 59- ACATCCCCTTGTGGAAAGTCCCTGCTGTTT-39
antisense), corresponding to bases 6194–6223 of HxBc2
enome and bases 9868–9898 of SIVmac239 genome,
espectively (Wong-Staal et al., 1985, Regier and Desro-
iers, 1990, Stephens et al., 1997). The amplified env, nef
ragments were separated on a 1% agarose gel, purified
rom the gel using GENECLEAN-II (Bio 101, Vista, CA),
nd cloned into the pGEM-T vector (Promega, Madison,
I). Clones containing inserts of the proper size were
equenced by primer-directed dideoxy sequencing using
equence enzyme (U.S. Biochemicals, Cleveland, OH)
nd 35S-ATP. The HIV-1 env sequence was compared
ith the parental HxB2 and SHIVKU-1 consensus se-
uences with the use of PCGENE sequence analysis
oftware programs.onstruction of chimeric virus SHIVKU-1bMC17
Clone 2, containing SHIVKU-1b env, nef, was used to
onstruct this virus (Fig. 3). This plasmid was digested
ith KpnI and NcoI to release a 3-kb fragment containing
ll of the env except for the first 127 bp and part of the nef
ene. The envelope fragment was purified by agarose
el electrophoresis and GENECLEAN-II according to the
anufacturer’s instructions. The corresponding region
rom the SHIV-4 was excised in the same manner. The
HIVKU-1b env, nef fragment was ligated into the 39
HIV-4 background according to manufacturer’s instruc-
ions (T4 DNA ligase; NEB) and used to transform com-
etent DH5a Escherichia coli. Clones containing an in-
ert of the correct size were sequenced to verify that the
nv was from SHIVKU-1b. For generation of SHIVKU-1bMC17
irus, the 59 SHIV-4 and 39 SHIV-4 plasmids containing
HIVKU-1b env were digested to completion with SphI,
igated using T4 DNA ligase, and transfected into C8166
ells using the DEAE-dextran method as previously de-
cribed (Millman and Herzberg, 1981).
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